Holen Sie sich die Stockscreener-App
5.14
3.75%
-0.20
Handel nachbörslich:
5.14
Schlusskurs vom Vortag:
$5.34
Offen:
$5.43
24-Stunden-Volumen:
12,331
Relative Volume:
0.19
Marktkapitalisierung:
$133.71M
Einnahmen:
$40,000
Nettoeinkommen (Verlust:
$-67.82M
KGV:
-1.4445
EPS:
-3.5583
Netto-Cashflow:
$-20.86M
1W Leistung:
-6.20%
1M Leistung:
+7.53%
6M Leistung:
-40.06%
1J Leistung:
-28.81%
1-Tages-Spanne:
$5.09
$5.43
1-Wochen-Bereich:
$5.09
$5.66
52-Wochen-Spanne:
$3.20
$12.99
Neonc Technologies Holdings Inc Stock (NTHI) Company Profile
Firmenname
Neonc Technologies Holdings Inc
Sektor
Branche
Telefon
310 663 7831
Adresse
23975 PARK SORRENTO, CALABASAS
Compare NTHI vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTHI
Neonc Technologies Holdings Inc
|
5.14 | 138.91M | 40,000 | -67.82M | -20.86M | -3.5583 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neonc Technologies Holdings Inc Aktie (NTHI) Neueste Nachrichten
NeOnc Technologies Holdings (NTHI) Holds Near Support as Modest Decline Tests Key LevelFactor Valuation - Newser
NTHI Initiated Coverage by Alliance Global Partners -- Rating Se - GuruFocus
NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones - The Manila Times
NeOnc Technologies Gains Analyst Favor with Growing Insider and Institutional Interest in CNS Cancer Therapies - Quiver Quantitative
Wall Street firms back brain-cancer biotech as trial data nears - Stock Titan
A. G. P. Initiates NeOnc Technologies(NTHI.US) With Buy Rating, Announces Target Price $13 - Moomoo
NeOnc Technologies Reports Q1 2026 Results: Advancing Phase 2 CNS Cancer Trials and Strengthening Financial Position 1 2 3 - Minichart
NeOnc Provides Business Update and Reports Q1 2026 Financial Results - Sahm
NeOnc Advances Glioma Programs and Strengthens Financial Position - TipRanks
NeOnc Technologies Price Target Announced at $20.00/Share by Maxim Group - Moomoo
NeOnc Technologies (Nasdaq: NTHI) posts Q1 loss, advances NEO212 and NEO100 - Stock Titan
NeOnc Technologies Holdings, Inc. Reports Q1 2026 Financial Results and Advances Key CNS Cancer Clinical Programs - Quiver Quantitative
Brain cancer drug developer NeOnc eyes FDA talks after $10M investment - Stock Titan
Maxim Group initiates coverage of Neonc Technologies Holdings (NTHI) with buy recommendation - MSN
Cinctive Capital (NTHI) reports 2.48M shares, including 1.06M warrants - Stock Titan
NEONC TECHNOLOGIES HOLDINGS, INC. 1Q 2026: Revenue $0 EPS $(0.38) — 10-Q Summary - TradingView
NeOnc Technologies (NASDAQ: NTHI) burns cash, flags going-concern risk despite $13.1M PIPE - Stock Titan
NeOnc Technologies Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
NeOnc Technologies Holdings, Inc.Common Stock (NQ: NTHI - The Chronicle-Journal
Number of shareholders of NeOnc Technologies Holdings, Inc. – NASDAQ:NTHI - TradingView
Neonc Technologies : NTHI - 24/7 Wall St.
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6 - Yahoo Finance
NeOnc Technologies Holdings, Inc. (NTHI) Stock Price, News, Quote & History - Yahoo! Finance Canada
NeOnc Technologies (NASDAQ:NTHI) Positioned for Potential Breakthrough in Brain Cancer Treatment Amidst Biotech Market Shift - Quiver Quantitative
A biotech CEO spent $500K+ as a brain cancer trial nears data - Stock Titan
Biotech’s Next Wave May Already be in Motion - marketscreener.com
The quiet strength in NeOnc (NTHI) business model (Surges Ahead) 2026-05-06Day Trade - newser.com
CEO buys $500K+ in brain-cancer biotech with trial data expected - Stock Titan
Where Executives Are Doubling Down on Their Companies’ Fortunes - marketscreener.com
NeOnc Technologies Holdings, Inc. 2025 10-K/A: Executive Compensation, Beneficial Ownership, and Key Agreements Overview - Minichart
NeOnc CEO purchases over $500,000 in company shares By Investing.com - Investing.com South Africa
NeOnc CEO purchases over $500,000 in company shares - Investing.com
NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts - The Manila Times
$500K more from NeOnc's CEO ahead of brain cancer drug data - Stock Titan
NeOnc Technologies Holdings Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
Executive pay, ownership and governance at NeOnc Technologies (NTHI) - Stock Titan
NeOnc Technologies President Makes Bold Insider Move Signaling Growing Confidence - TipRanks
Neonc president Amir Heshmatpour buys $41,592 of common stock By Investing.com - Investing.com Australia
Neonc president Amir Heshmatpour buys $41,592 of common stock - Investing.com India
Neonc Technologies (NTHI) president adds 10,000 shares in open-market purchase - Stock Titan
NTHI News | NEONC TECHNOLOGIES HOLDINGS (NASDAQ:NTHI) - ChartMill
Neonc Technologies president Amir Heshmatpour buys $45,180 in stock By Investing.com - Investing.com South Africa
Insider Move: NeOnc Technologies President Quietly Boosts His Stake in the Company - TipRanks
NTHI - Finviz
Neonc Technologies (NTHI) insider adds 10,000-share stake - Stock Titan
NTHI SEC FilingsNeOnc Technologies Holdings Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Neonc Technologies president Amir Heshmatpour buys $45,180 in stock - Investing.com
This Walker & Dunlop analyst begins coverage on a bullish note; here are top 5 initiations for Friday - MSN
Finanzdaten der Neonc Technologies Holdings Inc-Aktie (NTHI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Neonc Technologies Holdings Inc-Aktie (NTHI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Heshmatpour Amir F | President |
Apr 28 '26 |
Buy |
4.52 |
10,000 |
45,180 |
3,062,000 |
| Neman-Ebrahim Yousha | Chief Clinical Officer |
Apr 23 '26 |
Buy |
4.88 |
500 |
2,440 |
134,760 |
| Heshmatpour Amir F | President |
Apr 23 '26 |
Buy |
4.90 |
10,000 |
49,000 |
3,052,000 |
| SUH, DAVID JR. | Chief Accounting Officer |
Apr 09 '26 |
Buy |
5.00 |
200 |
1,000 |
111,866 |
| Heshmatpour Amir F | President |
Apr 10 '26 |
Buy |
4.89 |
10,000 |
48,950 |
3,042,000 |
| Heshmatpour Amir F | President |
Apr 08 '26 |
Buy |
5.61 |
10,000 |
56,050 |
3,027,000 |
| Heshmatpour Amir F | President |
Apr 09 '26 |
Buy |
5.19 |
5,000 |
25,950 |
3,032,000 |
| Heshmatpour Amir F | President |
Apr 02 '26 |
Buy |
6.09 |
20,000 |
121,798 |
3,012,000 |
| Heshmatpour Amir F | President |
Apr 06 '26 |
Buy |
6.32 |
5,000 |
31,600 |
3,017,000 |
| Heshmatpour Amir F | President |
Nov 21 '25 |
Buy |
6.07 |
24,000 |
145,600 |
2,986,000 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):